Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLSNASDAQ:CRBUNASDAQ:DTILNASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$1.21-1.5%$1.36$1.10▼$3.38$67.31M3.22359,731 shs16,917 shsCRBUCaribou Biosciences$0.86-4.4%$1.11$0.66▼$4.42$79.61M2.361.23 million shs474,247 shsDTILPrecision BioSciences$4.32-5.2%$5.04$3.61▼$14.66$45.23M1.59173,665 shs87,413 shsSGMOSangamo Therapeutics$0.71+2.0%$0.94$0.30▼$3.18$160.22M1.576.82 million shs3.59 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis+0.99%-2.38%+0.82%-36.27%-55.27%CRBUCaribou Biosciences+13.35%+4.01%-18.96%-47.94%-79.92%DTILPrecision BioSciences-1.52%-2.99%-10.78%+1.11%-67.12%SGMOSangamo Therapeutics+11.29%+6.97%-29.32%-42.49%+24.24%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis2.5757 of 5 stars3.53.00.00.02.22.50.6CRBUCaribou Biosciences3.1021 of 5 stars3.53.00.00.03.43.30.6DTILPrecision BioSciences4.4653 of 5 stars3.54.00.04.63.01.71.3SGMOSangamo Therapeutics1.497 of 5 stars3.31.00.00.02.40.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 3.00Buy$7.00478.03% UpsideCRBUCaribou Biosciences 3.00Buy$10.331,107.17% UpsideDTILPrecision BioSciences 3.00Buy$37.67772.92% UpsideSGMOSangamo Therapeutics 2.67Moderate Buy$5.17624.64% UpsideCurrent Analyst Ratings BreakdownLatest CRBU, CLLS, DTIL, and SGMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/7/2025SGMOSangamo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/28/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/19/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/19/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/18/2025SGMOSangamo TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$2.00 ➝ $2.002/19/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.001/27/2025SGMOSangamo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.001/23/2025SGMOSangamo TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.001/10/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.001/10/2025DTILPrecision BioSciencesBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$34.00 ➝ $34.00(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$41.51M1.62N/AN/A$1.52 per share0.80CRBUCaribou Biosciences$9.99M7.97N/AN/A$4.17 per share0.21DTILPrecision BioSciences$68.70M0.66N/AN/A$4.53 per share0.95SGMOSangamo Therapeutics$57.80M2.77$0.02 per share30.42$0.47 per share1.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$101.06M-$0.83N/AN/AN/A-234.39%-74.55%-22.65%5/5/2025 (Estimated)CRBUCaribou Biosciences-$102.07M-$1.65N/AN/AN/A-1,290.81%-45.46%-38.07%5/6/2025 (Estimated)DTILPrecision BioSciences-$61.32M$1.9071.93N/AN/A11.48%-23.69%-6.98%5/12/2025 (Estimated)SGMOSangamo Therapeutics-$257.83M-$0.52N/AN/AN/A-257.87%-264.16%-107.24%5/8/2025 (Estimated)Latest CRBU, CLLS, DTIL, and SGMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SGMOSangamo Therapeutics-$0.12N/AN/AN/A$7.90 millionN/A5/6/2025Q1 2025CRBUCaribou Biosciences-$0.42N/AN/AN/AN/AN/A3/26/2025Q4 2024DTILPrecision BioSciences-$2.09-$3.20-$1.11-$2.22$4.28 million$3.47 million3/17/2025Q4 2024SGMOSangamo Therapeutics-$0.09-$0.11-$0.02-$0.11$11.70 million$7.55 million3/13/2025Q4 2024CLLSCellectis$0.06-$0.16-$0.22-$0.15$5.90 million$33.22 million3/10/2025Q4 2024CRBUCaribou Biosciences-$0.40-$0.39+$0.01-$0.39$2.11 million$2.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.481.781.78CRBUCaribou BiosciencesN/A7.387.38DTILPrecision BioSciences0.349.229.22SGMOSangamo TherapeuticsN/A1.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%CRBUCaribou Biosciences77.51%DTILPrecision BioSciences37.99%SGMOSangamo Therapeutics56.93%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%CRBUCaribou Biosciences9.50%DTILPrecision BioSciences4.00%SGMOSangamo Therapeutics2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis29055.58 million46.46 millionOptionableCRBUCaribou Biosciences10093.01 million81.95 millionOptionableDTILPrecision BioSciences20010.48 million7.36 millionNo DataSGMOSangamo Therapeutics480224.71 million202.81 millionOptionableCRBU, CLLS, DTIL, and SGMO HeadlinesRecent News About These CompaniesSangamo Therapeutics' (SGMO) Buy Rating Reaffirmed at HC WainwrightApril 9 at 9:01 AM | marketbeat.comLilly, Sangamo Enter Capsid License AgreementApril 8 at 10:13 AM | contractpharma.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Down 15.51%April 8 at 10:13 AM | aaii.comLilly Throws Sangamo a Lifeline with Pact Worth Potential $1.4B+April 5, 2025 | biospace.comAnother rebound as Sangamo inks $1.4B capsid deal with LillyApril 5, 2025 | bioworld.comSangamo Thera enters critical deal with LillyApril 5, 2025 | thepharmaletter.comLilly throws lifeline to Sangamo with $1.4bn licensing dealApril 4, 2025 | pharmaphorum.comSangamo up 53% to 95c after announcing license pact with Eli LillyApril 4, 2025 | markets.businessinsider.comSangamo announces capsid license agreement with Eli LillyApril 3, 2025 | markets.businessinsider.comShares of Sangamo Therapeutics Rally on Licensing Deal With Eli LillyApril 3, 2025 | marketwatch.comSangamo Therapeutics Enters Capsid License Agreement With LillyApril 3, 2025 | marketwatch.comSangamo Therapeutics stock soars on Lilly licensing dealApril 3, 2025 | investing.comSangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous SystemApril 3, 2025 | finance.yahoo.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Down 13.07%April 2, 2025 | aaii.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Down 20.19%April 1, 2025 | aaii.comSouth Central & Sangamo split at 1st inter-conference All-Star gameMarch 31, 2025 | newschannel20.comTruist Financial Sticks to Its Buy Rating for Sangamo Biosciences (SGMO)March 19, 2025 | markets.businessinsider.comSangamo Therapeutics (NASDAQ:SGMO) Receives Sector Perform Rating from Royal Bank of CanadaMarch 19, 2025 | marketbeat.com3SGMO : 8 Analysts Assess Sangamo Therapeutics: What You Need To KnowMarch 18, 2025 | benzinga.comSangamo Therapeutics (NASDAQ:SGMO) Announces Earnings Results, Misses Estimates By $0.02 EPSMarch 18, 2025 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Posts Earnings ResultsMarch 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBU, CLLS, DTIL, and SGMO Company DescriptionsCellectis NASDAQ:CLLS$1.21 -0.02 (-1.54%) As of 01:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Caribou Biosciences NASDAQ:CRBU$0.86 -0.04 (-4.41%) As of 01:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Precision BioSciences NASDAQ:DTIL$4.32 -0.24 (-5.16%) As of 01:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Sangamo Therapeutics NASDAQ:SGMO$0.71 +0.01 (+2.05%) As of 01:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Delta, Walmart Cut Profit Targets: Could Start Domino Effect Joby Aviation: Operational Momentum vs. Market Sentiment Carvana: Can Turnaround Strength Outdrive Market Headwinds? Is Alphabet a Generational Buying Opportunity at These Levels? Meta Seeks Trump's Help in FTC Trial: The Implications Are Huge Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
